Artificial Intelligence in Pathology Market Report 2026

The artificial intelligence in pathology market size has grown rapidly in recent years. It will grow from $1.38 billion in 2025 to $1.57 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to increasing digitization of pathology workflows, rising demand for accurate cancer diagnostics, expansion of pharmaceutical research activities, adoption of digital slide scanners, growing availability of medical imaging datasets.

The artificial intelligence in pathology market size is expected to see rapid growth in the next few years. It will grow to $2.57 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to increasing use of AI-assisted diagnostics, rising focus on personalized medicine, expansion of AI integration in clinical decision support, growing investments in digital healthcare infrastructure, increasing regulatory approvals for AI-based pathology tools. Major trends in the forecast period include increasing adoption of AI-based digital pathology platforms, rising use of deep learning for tumor detection, growing integration of whole slide imaging systems, expansion of predictive analytics in disease diagnosis, enhanced focus on workflow automation in pathology labs.

The growing demand for personalized medicine is expected to drive the growth of the artificial intelligence (AI) in pathology market in the coming years. Personalized medicine involves tailoring medical treatments and healthcare approaches to the unique characteristics, needs, and preferences of each patient. This rising demand is driven by the goal of customizing treatments based on individual genetic profiles, lifestyle factors, and specific disease characteristics, thereby enhancing efficacy and minimizing adverse effects. AI in pathology supports personalized medicine by enabling more accurate and efficient analysis of medical images and genetic data, allowing for precise diagnoses, better identification of disease subtypes, and customized treatment plans aligned with a patient’s unique biological profile. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based professional membership organization, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 20 new personalized medicines, representing approximately 38 % of all newly approved therapeutic molecular entities - a significant increase compared with previous years. Thus, the increasing demand for personalized medicine is fueling the growth of the AI in pathology market.

Key players in the artificial intelligence (AI) in pathology market are focusing on developing advanced solutions, such as multi-tissue cancer detection tools, to improve diagnostic accuracy, streamline workflows, and enhance patient outcomes. AI-powered multi-tissue cancer detection tools utilize foundation models and deep-learning algorithms to analyze digitized pathology slides, enabling detection across various tissue types, including rare tumors and metastatic deposits. For example, in January 2024, Paige, a U.S.-based digital pathology company, introduced a new AI application built on its foundation model, Virchow, capable of detecting cancer across more than 17 different tissue types. This solution is designed to support pathologists by providing improved diagnostic accuracy, faster workflow efficiency, and actionable insights for personalized patient care.

In March 2023, Clarapath, a US-based medical robotics firm, acquired Crosscope for an undisclosed amount. This acquisition aims to enhance Crosscope's digital pathology platform by integrating advanced workflow tools and AI capabilities with Clarapath's automated tissue sectioning system, ultimately improving efficiency and accuracy in pathology laboratories. Crosscope is a US-based company that develops a digital pathology imaging platform that incorporates artificial intelligence to enhance analysis and diagnostics in the field of pathology.

Major companies operating in the artificial intelligence in pathology market are F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Hamamatsu Photonics K.K., Leica Biosystems, Tempus Labs Inc., Spectra AB, Lunit Inc., Paige AI Inc., Inspirata Inc., Indica Labs Inc., Flagship Biosciences Inc, Proscia Inc., Aiforia Technologies Oy, Lumea Inc., Optrascan Inc., PathAI Inc., Visiopharm A/S, Ibex Medical Analytics Ltd., BioSymetrics Inc., Deep Bio Inc., Konfoong Biotech International Co Ltd., Mindpeak GmbH, Qritive Inc., Vuno Inc.

Asia-Pacific was the largest region in the artificial intelligence in pathology market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence in pathology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence in pathology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the artificial intelligence in pathology market by increasing costs of imported digital scanners, high-resolution imaging sensors, graphic processing units, and advanced computing hardware required for AI model training and deployment. Hospitals, diagnostic laboratories, and research institutions in North America and Europe are most affected due to reliance on imported imaging and computing equipment, while Asia-Pacific faces higher costs for scanner manufacturing and export. These tariffs are raising capital investment requirements and slowing technology upgrades. However, they are also encouraging localized hardware assembly, domestic software development, and regional AI innovation ecosystems that support long-term market growth.

The artificial intelligence in pathology market research report is one of a series of new reports that provides artificial intelligence in pathology market statistics, including artificial intelligence in pathology industry global market size, regional shares, competitors with a artificial intelligence in pathology market share, detailed artificial intelligence in pathology market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in pathology industry. This artificial intelligence in pathology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI) in pathology refers to the application of machine learning algorithms and deep learning models to assist in the analysis of medical images, pattern recognition, and disease diagnosis. AI aids pathologists by automating tasks such as slide analysis, tumor detection, and grading, thereby enhancing diagnostic accuracy and efficiency. It also enables quicker processing of large datasets, which is essential for personalized medicine.

The primary components of artificial intelligence in pathology include software and scanners. Software consists of a collection of programs and algorithms specifically designed to perform tasks related to pathology, such as analyzing medical images, managing data, and supporting diagnostic and research activities. This technology employs various types of neural networks, including generative adversarial networks, convolutional neural networks, conventional neural networks, recurrent neural networks, and others. AI in pathology is utilized in drug discovery, disease diagnosis and prognosis, clinical workflows, as well as training and education. The users of these technologies encompass pharmaceutical and biotechnology companies, hospitals and reference laboratories, and academic and research institutions.

The artificial intelligence in pathology market consists of revenues earned by entities by providing services such as automated diagnostics, image analysis and interpretation, workflow optimization, and remote and telepathology. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence in pathology market also includes sales of high-resolution scanners, graphics processing units (GPUs), workstations, and storage systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.